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Background
Anti-TNF agents are frequently used in the treatment of
severe rheumatic disorders in childhood mainly Juvenile
Idiopathic arthritis. Despite good clinical efficacy of this
therapy, practitioners must remain alert for potential
side effects, particularly after prolonged use (infections,
malignancy and autoinmune events) .
Objective
Anti-TNF (Etanercept, infliximad and adalimumab)
related adverse events were consecutively recorded and
analized in pediatric patients with rheumatic disorders
followed in our section from 2000 to 2010.
Methods
Time of exposure, dose and reason for discontinuation
were recorded Analysis involved incidence rate, out-
come, and causal relationship. Statiscal analysis were
performed using SPSS software.
Results
Data from 131 clinical records were analyzed . 87(66.4%)
were female, median age at diagnosis 7.2 (RIQ 3.8-11.3),
median follow up 7.9 ys (SD±4.8). 111 pts had JIA,5
JDM ,4 vasculitis, 3 sarcoidosis, 2MCTD,1SLE and 5
idiopathic uveitis.
Most of the AEs were mild: 28,2% and 13,5 upper
respiratory and skin infections respectively.
Four pts developed autoinmune events: Lupus –like
syndrome, Psoriasis and 2 other ,optic neuritis .One pt
under IFX + MTX developed Non-Hodgkin Limphoma
and another on IFX fatal fulminant hepatitis.
Conclusions
In our series we observed a total of 156 AEs with inci-
dence rates of: 0.3, 0.5 and 0.9 with Etanercept,adalimu-
mab and infliximab respectively.
Seven pts developed SAEs including opportunistic
infections (TB), serious infusion reactions ,NHL and ful-
minant hepatitis. Eigtheen pts (13,8 %) discontinued
antiTNF therapy due adverse events.
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Table
Etanercept Infliximab Adalimumab
Number of treatments 105 43 12
Mean age at onset,ys (SD) 11.2 (4.8) 12.5 (4.1) 16.4 (3.8)
Exposure time (pts-year) 246,5 82,7 9,2
Adverse events 75 76 5
Incidente rate AE 0.3 0.9 0.5
SAE (incidente rate) 2 (0.008) 5 (0.06) 0 (0)
Opportunistic infections
(Tuberculosis)
12 0
Discontinuation due to AE n (%) 5 (4.8) 13 (30.2) 0
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